Involvement of oxytocin in spinal antinociception in rats with inflammation.
The present study was conducted on rats with inflammation induced by subcutaneous injection of carrageenan into the left hindpaw. Intrathecal administration of oxytocin produced dose-dependent increases in the hindpaw withdrawal latency (HWL) to thermal and mechanical stimulation in rats with inflammation. The antinociceptive effect of oxytocin was blocked by intrathecal administration of atosiban, a selective oxytocin antagonist, indicating that oxytocin receptor mediates oxytocin-induced antinociception in the spinal cord. The oxytocin-induced antinociceptive effect was attenuated by intrathecal administration of the opioid antagonist naloxone, suggesting an involvement of the endogenous opioid system in oxytocin-induced antinociception in the spinal cord of rats with inflammation. Furthermore, the antinociceptive effect of oxytocin was attenuated by intrathecal injections of the mu-receptor antagonist beta-funaltrexamine and the kappa-receptor antagonist nor-binaltorphimine, but not by the delta-receptor antagonist naltrindole, illustrating that mu- and kappa-receptors, but not delta-receptor, are involved in oxytocin-induced antinociception in the spinal cord of rats with inflammation. Moreover, intrathecal administration of atosiban alone induced a hyperalgesia in rats with inflammation, indicating that endogenous oxytocin is involved in the transmission and regulation of nociceptive information in the spinal cord of rats with inflammation. The present study showed that both exogenous and endogenous oxytocin displayed antinociception in the spinal cord in rats with inflammation, and mu- and kappa-receptors were involved in oxytocin-induced antinociception.
Yu
Shuang Quan
SQ
Neurobiology Laboratory, College of Life Sciences, and Center for Brain and Cognitive Science and National Laboratory of Biomembrane and Membrane Biotechnology, Peking University, 100871, Beijing, China.
Lundeberg
Thomas
T
Yu
Long Chuan
LC
D000700:Analgesics; D000818:Animals; D002351:Carrageenan; D006358:Hot Temperature; D007249:Inflammation / Q000139:chemically induced / Q000150:complications* / Q000473:pathology; D007278:Injections, Spinal; D008297:Male; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D009271:Naltrexone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D010121:Oxytocin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010146:Pain / Q000209:etiology*; D010147:Pain Measurement / Q000187:drug effects; D010812:Physical Stimulation; D051381:Rats; D017208:Rats, Wistar; D013116:Spinal Cord / Q000502:physiology*; D014668:Vasotocin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D000700:Analgesics; D009292:Narcotic Antagonists; C047046:atosiban; D009270:Naloxone; C051844:norbinaltorphimine; D010121:Oxytocin; D009271:Naltrexone; C024524:beta-funaltrexamine; D002351:Carrageenan; C055382:naltrindole; D014668:Vasotocin